Cyclerion Therapeutics Inc (CYCN) Stock Price, Quote & News

Company Profile

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebi...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8778

Website: www.cyclerion.com

Address:

245 First Street, Riverview II, 18th Floor, Cambridge, United States

StockTwitsGhost Aug. 19 at 7:53 AM

$CYCN https://emeraldinno.com/platform/

0 · Reply

StockTwitsGhost Aug. 19 at 12:06 AM

$CYCN I've mentioned this before that I fully expect Cyclerion to dust off old relationships rather than reinvent the wheel. Westover is exactly that. Peter Hecht appears to be a creature of habit as can be seen with his companies Ironwood, Cyclerion, and Tisento. They return to the same financing, legal, CPA, colleagues, and science. I've also posted months ago that based on the circular nature of CYCN, Beacon makes a lot of sense. The only issue though is Cyclerion requires real-time biofeedback needs and Beacons is technically a misalignment with real-time biofeedback needs. The real reason though is Beacon has legitimate competitive overlap and IP concerns with Syndeio and Gate Neurosciences that could present a conflict of interest (zelquistinel may target overlapping patient populations (e.g. TRD). My speculative analysis is CYCN has sought a licensing opportunity with another company. I'll post more about that.

2 · Reply

EZYME22 Aug. 18 at 8:44 PM

$CYCN M. Brandon Westover former Cyclerion advisor and co-founder beacon biosignals

1 · Reply

StockTwitsGhost Aug. 18 at 7:44 PM

$CYCN After hours SEC filing. Just a hunch.

1 · Reply

AshleySchaeffer_BMW Aug. 18 at 7:10 PM

$CYCN achieve inner peace, buy more cycn today

0 · Reply

skyrockets_Inc Aug. 18 at 7:03 PM

$CYCN

0 · Reply

SDBiotechInvestor Aug. 18 at 5:21 PM

$CYCN - CVCO option agreement expires Friday. Let's see if we get, at minimum, an 8k about it.

0 · Reply

StockTwitsGhost Aug. 18 at 4:24 PM

$CYCN https://endpoints.news/reunions-psychedelic-approach-in-postpartum-depression-clears-phase-2-trial/?u=46893c55-325c-49cb-91b7-62841e056a23&s=email&c=79153abc-b399e7ac-275dc22d&utm_medium=email&utm_campaign=2269%20-%20Skyhawk%20inks%20another%20pharma%20deal%20A%20psychedelic%20drug%20for%20postpartum%20depression%20Basic&utm_content=2269%20-%20Skyhawk%20inks%20another%20pharma%20deal%20A%20psychedelic%20drug%20for%20postpartum%20depression%20Basic+CID_5f907e44dc4d6a6881368204430cf174&utm_source=ENDPOINTS%20emails&utm_term=Updated%20Reunions%20psychedelic%20approach%20in%20postpartum%20depression%20clears%20Phase%202%20trial

0 · Reply

AshleySchaeffer_BMW Aug. 18 at 1:22 PM

$CYCN will be a fun few weeks ahead for us cycleriooons

0 · Reply

BioTechHealthX Aug. 18 at 11:39 AM

$CYCN Cyclerion is transforming its sGC stimulator portfolio into a revenue powerhouse while building a next-generation CNS pipeline. https://biotechhealthx.com/biotech-news/cyclerion-therapeutics-cycn-poised-for-massive-growth-with-1-75m-license-deal/

0 · Reply

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Dec 4, 2023, 8:00 AM EST - 1 year ago

Cyclerion Appoints Regina Graul, Ph.D., as President

Nov 30, 2023, 6:16 PM EST - 1 year ago

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Jul 31, 2023, 7:00 AM EDT - 2 years ago

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Jun 1, 2023, 4:00 PM EDT - 2 years ago

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023, 1:00 PM EDT - 2 years ago

Cyclerion Announces Reverse Stock Split

May 11, 2023, 6:00 PM EDT - 2 years ago

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

May 11, 2023, 6:00 PM EDT - 2 years ago

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Apr 3, 2023, 7:30 AM EDT - 2 years ago

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

Mar 22, 2023, 4:40 PM EDT - 2 years ago

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Nov 22, 2022, 7:00 AM EST - 2 years ago

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Aug 9, 2022, 4:00 PM EDT - 3 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Jul 28, 2022, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Jul 26, 2022, 7:00 AM EDT - 3 years ago

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

Jun 28, 2022, 9:00 AM EDT - 3 years ago

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 22, 2022, 8:30 AM EDT - 3 years ago

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 17, 2022, 11:27 AM EDT - 3 years ago

Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Jun 17, 2022, 8:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Jun 10, 2022, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Jun 6, 2022, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

May 4, 2022, 4:01 PM EDT - 3 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Feb 24, 2022, 4:01 PM EST - 3 years ago

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Feb 23, 2022, 8:00 AM EST - 3 years ago

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Jan 26, 2022, 8:00 AM EST - 3 years ago

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

Nov 11, 2021, 5:32 PM EST - 4 years ago

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

Nov 9, 2021, 4:01 PM EST - 4 years ago

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Oct 26, 2021, 4:29 PM EDT - 4 years ago

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 20, 2021, 4:24 PM EDT - 4 years ago

Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside

Sep 22, 2021, 8:00 AM EDT - 4 years ago

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Aug 23, 2021, 5:00 PM EDT - 4 years ago

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Jul 29, 2021, 5:00 PM EDT - 4 years ago

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Jul 22, 2021, 4:30 PM EDT - 4 years ago

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)

Jul 9, 2021, 6:14 AM EDT - 4 years ago

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

Jul 8, 2021, 7:22 PM EDT - 4 years ago

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Jul 8, 2021, 4:30 PM EDT - 4 years ago

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Jun 4, 2021, 10:27 AM EDT - 4 years ago

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

AKBA

Jun 4, 2021, 8:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Jun 4, 2021, 8:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces $18 Million Private Placement

May 27, 2021, 4:30 PM EDT - 4 years ago

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

May 25, 2021, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Apr 27, 2021, 12:03 PM EDT - 4 years ago

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

BNGO ALDX SLGL

Apr 27, 2021, 9:00 AM EDT - 4 years ago

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress

Apr 26, 2021, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors

Apr 21, 2021, 7:30 AM EDT - 4 years ago

Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference

Apr 20, 2021, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics to Host Pipeline Update Webinar

Mar 18, 2021, 5:00 PM EDT - 4 years ago

Cyclerion Therapeutics Announces Departure of Chief Medical Officer

Jan 25, 2021, 7:00 AM EST - 4 years ago

Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards

StockTwitsGhost Aug. 19 at 7:53 AM

$CYCN https://emeraldinno.com/platform/

0 · Reply

StockTwitsGhost Aug. 19 at 12:06 AM

2 · Reply

EZYME22 Aug. 18 at 8:44 PM

$CYCN M. Brandon Westover former Cyclerion advisor and co-founder beacon biosignals

1 · Reply

StockTwitsGhost Aug. 18 at 7:44 PM

$CYCN After hours SEC filing. Just a hunch.

1 · Reply

AshleySchaeffer_BMW Aug. 18 at 7:10 PM

$CYCN achieve inner peace, buy more cycn today

0 · Reply

skyrockets_Inc Aug. 18 at 7:03 PM

$CYCN

0 · Reply

SDBiotechInvestor Aug. 18 at 5:21 PM

$CYCN - CVCO option agreement expires Friday. Let's see if we get, at minimum, an 8k about it.

0 · Reply

StockTwitsGhost Aug. 18 at 4:24 PM

0 · Reply

AshleySchaeffer_BMW Aug. 18 at 1:22 PM

$CYCN will be a fun few weeks ahead for us cycleriooons

0 · Reply

BioTechHealthX Aug. 18 at 11:39 AM

0 · Reply

BigSqueezeComing Aug. 18 at 11:02 AM

$CYCN gappers.

0 · Reply

StockTwitsGhost Aug. 16 at 9:56 PM

$CYCN This patent is exceptionally significant, representing the critical drug discovery-to-development transition. For CVCO, it transforms risk-reward calculations, making the licensing deal more valuable and fundable. For Cyclerion w/ a $10M MC, this olinciguat formulation patent is likely material given: small company size makes any major IP development significant; olinciguat is a core remaining asset; patent materially impacts pending CVCO licensing deal. If assesment is accurate, Cyclerion must file 8-K within 4 business days of Aug 15 patent publication, making deadline Thursday Aug 22 - coincidentally CVCO’s option expiration. Filing would be under Item 8.01 for material events. The aligned timing suggests coordinated disclosure of both patent breakthrough and deal completion. Given circumstances, not filing seems unlikely. IMO

2 · Reply

Bullbear1010101 Aug. 16 at 9:55 PM

$CYCN $GLTO yes 10 to 3.5 is quite a dip for something that theoretically could help long term acquired drug

0 · Reply

StockTwitsGhost Aug. 16 at 8:58 PM

$CYCN An announcement this week is highly reasonable. The patent publication represents the final piece of the puzzle CVCO needed to complete their due diligence and secure funding commitments. The convergence of the extension deadline with this critical IP publication suggests careful orchestration by both parties. The announcement would likely emphasize the enhanced commercial potential through improved formulation technology, providing both companies with a strong narrative for stakeholders and investors. The Strategic Importance of Formulation Patents This isn’t just any patent - it’s specifically focused on solid dispersions of amorphous olinciguat, which addresses a critical pharmaceutical development challenge. The patent describes methods to improve the drug’s bioavailability and stability, essential elements for commercial viability. For CVCO, this formulation breakthrough represents: De-risked Development, Competitive Advantage, Regulatory Pathway Clarity

2 · Reply

StockTwitsGhost Aug. 16 at 8:30 PM

$CYCN A comprehensive analysis of U.S. Patent US-20250255821-A1 and its chemical structure was performed using Anthropic Claude Opus 4.1 Enterprise Edition and three publicly available AI tools. All four AI models concluded that the compound described in the patent corresponds to the Olinciguat scaffold (IW-1701). The compound in the patent is described as:1,1,1,3,3,3‑hexafluoro‑2‑[((5‑fluoro‑2‑(1‑(2‑fluorobenzyl)‑5‑(isoxazol‑3‑yl)‑1H‑pyrazol‑3‑yl)pyrimidin‑4‑yl)amino)methyl]propan‑2‑ol. Based on the overall molecular scaffold pyrimidine‑pyrazole‑oxazole with a 2‑fluorobenzyl substituent attached via an aminomethyl linkage—the patent clearly aligns with Olinciguat, not Zagociguat. That said, the difference lies in the terminal moiety: * Olinciguat: features a trifluoromethyl‑substituted propanamide (i.e., –CF₃, –CONH₂). * Patent Compound I: specifies a hexafluoro‑propan‑2‑ol, meaning two CF₃ groups or different fluorination—the structure differs enough to be a novel modification.

1 · Reply

AshleySchaeffer_BMW Aug. 16 at 6:29 PM

$CYCN you got a sperg on this board pumpin bolt and bashin cyclerion, best medicine for him to take is some of his own, going to open up a huge steamy turd of a short on bolt next week…

1 · Reply

StockTwitsGhost Aug. 16 at 12:30 AM

$CYCN It's plausible that CVCO extended its licensing option for olinciguat to await the approval of this patent, published August 14, 2025. This strategic move would allow CVCO to secure enhanced intellectual property protections before finalizing the licensing agreement. CVCO is reportedly concluding a funding round, which aligns with the timing of the patent's approval. This suggests that CVCO may be preparing to exercise the licensing option, leveraging the strengthened intellectual property position to attract investors and secure favorable terms. This approach mirrors common industry practices, where licensing agreements are finalized after key intellectual property milestones are achieved, ensuring that the licensee acquires the most robust and protected version of the asset. CVCO's extensions and timing of the patent approval indicate a strategic effort to finalize the licensing agreement under optimal conditions, potentially enhancing the asset's value and appeal to investors.

3 · Reply

StockTwitsGhost Aug. 16 at 12:16 AM

$CYCN Cyclerion’s patent (US 2025/0255821 A1), published yesterday on August 14, 2025, delivers a highly significant advancement: solid dispersion formulations of sGC stimulators that dramatically enhance solubility, dissolution rate, stability, and oral bioavailability. Techniques like spray-drying and hot‑melt extrusion reflect clinically relevant, scalable formulation innovation. Launching immediately after Cyclerion’s December 2024 exclusive CVCO option agreement for olinciguat, this patent strengthens olinciguat’s IP profile by layering formulation claims—bolstering pharmacokinetics, extending market exclusivity, and raising its strategic value under the option’s IP-cost structure. Altogether, the timing, technical scope, and formulation focus of the patent present a powerful, plausible alignment with Cyclerion’s olinciguat licensing strategy, underscoring its commercial and therapeutic significance. https://ppubs.uspto.gov/api/patents/html/20250255821?source=US-PGPUB&requestToken=eyJzdWIiOiIwZmFjNDViZS1lNzc1LTRjMDMtYTlhYi1kYWUyN2VlNmUwNzMiLCJ2ZXIiOiJlZTE3ZmZjMS01NWIxLTQ3YzYtYmI2OS0yMjg2N2NlNTI2YjYiLCJleHAiOjB9

2 · Reply

BiotechValues Aug. 15 at 9:02 PM

$CYCN I'll only stop posting when my brother deletes all hi lies/posts on X and agrees to stop posting. Else I'm fine spending my days here reiterating the bear thesis

1 · Reply

BiotechValues Aug. 15 at 8:58 PM

$CYCN a great parallel to this bear thesis is what happened with $GLTO. Below is what happened when they formally announced their new strategy and timelines. I expect the same to happen with $CYCN. Will be a sell news event due to dilution and timelines:

1 · Reply

BiotechValues Aug. 15 at 8:54 PM

$CYCN in sum, the stock is overvalued, overhyped, and likely going to sell off when the Stocktwits manipulators all sell out the day of the formal new strategy being announced. In the meanwhile, they will try and bait you in, with sensational posts about huge gains, be careful

0 · Reply

BiotechValues Aug. 15 at 8:53 PM

$CYCN I plan to focus on this project for the next several months, and will post more to keep investors aware of the risks and what is actually happening here. The road is long, the dilution painful and I see little to get excited about

1 · Reply

Market Cap	7.86M
Revenue (ttm)	2.00M
Net Income (ttm)	-3.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-153.00%
Debt to Equity Ratio	0.00

Volume	14,900
Avg Vol	40,370
Day's Range	N/A - N/A
Shares Out	3.34M
Stochastic %K	73%
Beta	1.68
Analysts	Strong Buy
Price Target	$4.00